Ruggero Galici is Senior Director of Nonclinical and Clinical Pharmacology Medical Writing at Alexion Pharmaceuticals Inc, AstraZeneca Rare Disease Unit and heads up global early phase regulatory medical writing activities. In this role, he facilitates the transition of early phase programmes from first-in-human research to clinical trial applications and investigational new drug submissions.

Ruggero has a background in drug discovery, nonclinical and clinical development, a PhD in pharmacology, and post-doctoral training. He has led pharmacology teams to advance small molecules and biologics to the clinic and has served as subject matter expert to compound development teams. Ruggero has more than 20 years of experience in scientific and regulatory writing.

Medical Writing Editor-in-Chief Raquel Billiones asked him five questions about his career and expertise.

Medical Writing. 2023;32(4):18–19. https://doi.org/10.56012/msng4369